About Us

Corporate Profile



AT A GLANCE

Chairman and Co-Founder Milan Puskar
Vice Chairman and CEO Robert J. Coury
Corporate Headquarters Pittsburgh, Pennsylvania, United States
Founded 1961, White Sulphur Springs, West Virginia, United States
Employees Approx. 12,000
2006 Pro Forma Revenue US$4.2 Billion
Product Portfolio 570 Marketed Products
Commercial Footprint 92 Countries
Manufacturing Capacity 45 Billion Doses
Membership S&P 500
Stock Exchange Listing NYSE: MYL

PRIMARY BUSINESSES AND OPERATIONS

  • Generic Pharmaceuticals and Branded Generics
  • Specialty and Brand Pharmaceuticals
  • Active Pharmaceutical Ingredients

MYLAN’S GLOBAL OPERATIONS

North America
EMEA
APAC
Dey
Matrix Laboratories

» North America

A U.S. generic industry pioneer, Mylan Pharmaceuticals has remained committed to providing customers with an extensive line of high quality, affordable pharmaceuticals since 1961. With the acquisition of Merck Generics, Mylan added Genpharm, a top five player in the Canadian market. Together, along with UDL Laboratories and Mylan Technologies, Mylan is poised to expand its established North American presence.

Markets: United States, Canada
Key Local Operating Companies: Mylan Pharmaceuticals, Genpharm, Mylan Technologies, UDL Laboratories

» EMEA

With manufacturing, packaging, distribution and marketing capabilities, Mylan holds top five positions in nine different markets throughout Europe including No. 1 positions in France and Portugal and top 3 positions in the United Kingdom, Italy, Spain and Belgium.

Markets: Austria, Belgium, France, Germany, Greece, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, United Kingdom, Morocco and South Africa
Key Local Operating Companies: Merck Generiques, Merck Genericos (Spain and Portugal), Qualimed, Generics (UK) Limited, Merck Dura, Arcana, Merck NM, Generics Pharma Hellas, Gerard Laboratories, Merck Generics Holland, Merck Generics Belgium, Merck Generics Italy.
Docpharma: Through Matrix represented in the Benelux countries through Docpharma Belgium and Apothecon Netherlands.

» APAC

Mylan’s Asia-Pacific presence includes market leading positions in both Australia and New Zealand and a rapidly expanding presence in Japan. In Australia, Mylan’s local operating company, Alphapharm, is the largest pharmaceutical company in the country as measured by prescriptions.

Markets: Australia, Japan, New Zealand
Key Local Operating Companies: Alphapharm, Pacific Pharmaceuticals, Merck Seiyaku

» Dey

Dey L.P. is Mylan’s specialty pharmaceutical business. The company develops, manufactures and markets innovative airway and allergy medications and is among the top ten companies participating in the $16 billion respiratory market through leading products including DuoNeb®, Perforomist™ and EpiPen®. Dey is the No. 1 provider of nebulized products; No. 3 in the COPD market; and EpiPen® has 96% of the market for the treatment of severe allergic reaction.

» Matrix Laboratories

Mylan owns a controlling interest in Matrix Laboratories, which has the second largest API portfolio in the world. Based in Hyderabad, India, Matrix provides more API for antiretrovirals (ARV) used in the treatment of HIV/AIDS than any other company, leading the way in driving down the cost of HIV/AIDS medications. Matrix, itself, has several operating units including:

  • A network of 10 API manufacturing facilities across India, China and South Africa. Eight of these facilities have Global Regulatory approvals.
  • Docpharma, a distributor of generic pharmaceuticals in Belgium, the Netherlands and Luxembourg
  • Astrix Laboratories, a 50% owned joint venture (with Aspen Pharmacare) that manufactures ARV API and is based in India
  • Fine Chemicals Corporation, a 50% owned joint venture (with Aspen Pharmacare) that manufactures ARV API and is based in South Africa
  • Mchem Pharma Group, a 95% owned finished dose, API and intermediates manufacturer located in China
  • Concord Biotech, a 55% owned biotechnology company in India